nach oben

Wiener klinische Wochenschrift

Erschienen in:

01.12.2020 | editorial

Double trouble: severe aortic stenosis and cardiac amyloidosis

verfasst von: Christian Nitsche, MD, Julia Mascherbauer, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 23-24/2020

Einloggen, um Zugang zu erhalten

Excerpt

Aortic stenosis (AS) as well as cardiac amyloidosis (CA) are prevalent conditions in old patients. The combination of both AS and CA has recently been identified to occur in a significant number of patients scheduled for aortic valve replacement. Age alone, however, does not fully explain the frequent overlap of the two pathologies as the prevalence of CA in individuals >80 years in the general population has been described to be <1% [1]. …

Nächster Artikel Predicting the presence of coronary artery disease by transesophageal echocardiography

Longhi S, Guidalotti PL, Quarta CC, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging. 2014;7:531–2.CrossRef

Scully PR, Patel KP, Treibel TA, et al. Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart J. 2020;41(29):2759–2767. https://doi.org/10.1093/eurheartj/ehaa170.CrossRefPubMedPubMedCentral

Audet A, Côté N, Couture C, et al. Amyloid substance within stenotic aortic valves promotes mineralization. Histopathology. 2012;61:610–9.CrossRef

Treibel TA, Fontana M, Gilbertson JA, et al. Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement. Circ Cardiovasc Imaging. 2016;9(8):e005066. https://doi.org/10.1161/CIRCIMAGING.116.005066.CrossRefPubMed

Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404–12.CrossRef

Nitsche C, Aschauer S, Kammerlander AA, et al. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail. 2020 Feb 20. https://doi.org/10.1002/ejhf.1756. Epub ahead of print.CrossRefPubMedPubMedCentral

Rosenblum H, Masri A, Narotsky DL, et al. Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis. Eur J Heart Fail. 2020 Jul 30. https://doi.org/10.1002/ejhf.1974. Epub ahead of print.CrossRefPubMed

Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38:2879–87.CrossRef

Nitsche C, Scully PR, Patel KP, et al. Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis. J Am Coll Cardiol. 2020 Nov 5. https://doi.org/10.1016/j.jacc.2020.11.006. Epub ahead of print.CrossRefPubMed

10.

Pibarot P, Lancellotti P, Narula J. Concomitant Cardiac Amyloidois in Severe Aortic Stenosis: The Trojan Horse? J Am Coll Cardiol. 2020 Nov 6. https://doi.org/10.1016/j.jacc.2020.11.007. Epub ahead of print.CrossRefPubMedPubMedCentral

11.

Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379:1007–16.CrossRef

12.

Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:22–31.CrossRef

13.

Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379:11–21.CrossRef

14.

Fontana M, Martinez-Naharro A, Chacko L, et al. Reduction in CMR Derived Extracellular Volume with Patisiran Indicates Cardiac Amyloid Regression. JACC Cardiovasc Imaging. 2020 Oct 28. https://doi.org/10.1016/j.jcmg.2020.07.043. Epub ahead of print.CrossRefPubMed

Titel: Double trouble: severe aortic stenosis and cardiac amyloidosis
verfasst von: Christian Nitsche, MD
Julia Mascherbauer, MD
Publikationsdatum: 01.12.2020
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 23-24/2020
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-020-01787-7

Springer Medizin Österreich

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 23-24/2020

Recommendations on the utilization of telemedicine in cardiology

Veranstaltungstipps:

Predicting the presence of coronary artery disease by transesophageal echocardiography

Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement

A little is better than none: the biggest gain of physical activity in patients with ischemic heart disease

Toxoplasma infection in patients with myocardial infarction